Medium Biosciences is a software platform that utilizes AI to design protein therapeutics for industrial biotechnology companies. It streamlines the development process, enabling faster and more efficient creation of targeted therapies to meet specific medical needs.
Funding
$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Industrial biotechnology companies face challenges in efficiently designing protein therapeutics with desired properties, leading to lengthy development cycles and high costs. Traditional methods often involve extensive trial-and-error, limiting the speed and effectiveness of creating targeted therapies.
Solution
Medium Biosciences offers a software platform that leverages artificial intelligence to accelerate the design of protein therapeutics. The platform streamlines the development process by predicting protein structures and optimizing their functions for specific applications. By using AI algorithms, the platform enables faster and more efficient creation of targeted therapies, reducing the time and resources required for traditional methods. This allows companies to quickly identify and develop promising protein candidates with enhanced efficacy and reduced development costs.
Target Audience
The primary customers are industrial biotechnology companies involved in the development of protein therapeutics.
Features
- AI-driven protein design platform
- Predictive modeling of protein structures
- Optimization of protein functions for specific applications
- Streamlined development process
- Faster identification of promising protein candidates